Cangrelor Survives Second Advisory Committee, But Narrowly
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA panel members were not enthusiastic about the antiplatelet, but felt it could help ‘some people.’
You may also be interested in...
Cangrelor Advisory Cmte. Unsure Whether Plavix Even Needs Replacing
After a brutal panel review, The Medicines Co.’s best chance for its anti-clotting medication may be to create a “better sense of the unmet need” in the perioperative setting when Plavix use must be suspended.
Cangrelor Can’t Escape Its Past At FDA Advisory Committee
The Medicines Co.’s anti-clotting drug had one relatively positive study, but two failed ones, and that produced two lopsided “no” votes by the Cardiovascular and Renal Drugs Advisory Committee.
CDER, CBER Not Seeing Hiring Slowdown Despite US FDA Warnings
FDA officials have said hiring could be slowed if an inflationary pay increase is not included in the agency budget, but CDER and CBER continue to add staff at a steady pace.